About Us

Led by a team of distinguished life sciences leaders, Kiniksa is a global biopharmaceutical company that finds and delivers novel treatments for patients with a significant unmet need. 

 

Our Mission

We’re relentless and focused on putting patients at the center of everything we do as we strive to develop life-changing medicines.

hear
Joao's story

Living with
Recurrent Pericarditis

hear
Jill's story

Living with
Recurrent Pericarditis

hear
Nadine's story

Living with
Recurrent Pericarditis

Our History

 

Image
Our History

Founded in 2015 in Bermuda, with US subsidiary headquarters in Massachusetts, Kiniksa Pharmaceuticals has grown into a global biopharmaceutical company with a seasoned team that commercializes and advances a pipeline of product candidates for patients with devastating diseases.

 

The team members at Kiniksa have a duty to our patients, and you can see that responsibility and focus in where we are, where we’ve been, and where we plan to go.

Key Milestones

2021
Q2
FDA approval and commercial availability of first and only FDA-approved therapy for recurrent pericarditis on prescription basis in the US.
Q2
Kiniksa announces positive results for mavrilimumab Phase 2 trial in non-mechanically ventilated severe COVID-19 patients.
2020
Q3
FDA grants Orphan Drug designation for rilonacept and mavrilimumab.
Q4
FDA grants Breakthrough Therapy designation to vixarelimab for pruritus associated with prurigo nodularis.
2019
Q4
Initiates a first-in-human study with antigen challenge TDAR for KPL-404.
Q4
FDA grants Breakthrough Therapy designation for rilonacept for recurrent pericarditis and final Phase 2 clinical data presented at the American Heart Association 2019 Scientific Sessions.
2018
Q2
Raises $170.7M in gross proceeds from IPO.
Q2
Presents initial proof-of-concept data for rilonacept.
2017
Q3
Acquires the rights to rilonacept and receives an exclusive option to acquire KPL-404.
2016
Q3
Acquires the worldwide rights to our first program (rilonacept) and initiates IND-enabling activities.
2015
Q4
Kiniksa raises $80M in committed Series A capital to focus on rapidly bringing therapies to patients who have unmet needs.